Published October 10, 2024
| Version v1
Journal
Open
Satiety hormone LEAP2 after low-calorie diet with/without Endobarrier insertion in obesity and type 2 diabetes mellitus (supplementary material)
Description
Supplementary material for publication
Files
Emini Bhargava LEAP2 obesity T2DM LCD DJBL J Endo Soc 2024 Suppl material.pdf
Files
(1.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:e3c52d69d013943aec102b426b212b4c
|
1.6 MB | Preview Download |
|
md5:767d5a5071f079a66ba7b8989519452f
|
247.6 kB | Download |
Additional details
Funding
- UK Research and Innovation
- Human experimental medicine studies of gut hormone LEAP2, an endogenous ghrelin antagonist and target for obesity, diabetes, cachexia and addiction MR/T017279/1
- UK Research and Innovation
- A randomized controlled trial of a duodenal sleeve bypass device (Endobarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes MC_PC_14139